Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of.
TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19 forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
AUSTIN, Texas, May 25, 2021 (GLOBE NEWSWIRE) TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on
Tuesday, June 1, 2021 at 11:30am EST.
To register in advance for the corporate presentation, sign up here.
Replay Link:
A replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at https://ir.tffpharma.com/events-and-presentations/events
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform